$PBLA
Panbela Therapeutics, Inc.

2016 Q1 Form 10-K Financial Statement

#000143774916027017 Filed on March 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q4 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $480.0K $370.0K $240.0K
YoY Change -60.0% 54.17% 71.43%
% of Gross Profit
Research & Development $494.0K $920.0K $670.0K
YoY Change -49.95% 37.31% 139.29%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $494.0K $1.280M $920.0K
YoY Change -49.95% 39.13% 119.05%
Operating Profit -$975.0K
YoY Change -55.34%
Interest Expense $45.00K -$60.00K -$70.00K
YoY Change -4.26% -14.29% 600.0%
% of Operating Profit
Other Income/Expense, Net $36.00K -$20.00K -$30.00K
YoY Change -155.38% -33.33%
Pretax Income -$939.0K -$1.370M -$1.020M
YoY Change -58.23% 34.31% 5000.0%
Income Tax -$115.0K -$640.0K -$50.00K
% Of Pretax Income
Net Earnings -$824.0K -$730.0K -$980.0K
YoY Change -62.39% -25.51% 4800.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$274.2K -$237.8K -$1.922M
COMMON SHARES
Basic Shares Outstanding 29.89M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q4 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $380.0K $930.0K $2.150M
YoY Change 58.33% -56.74% 3483.33%
Cash & Equivalents $383.0K $925.0K $1.654M
Short-Term Investments $500.0K
Other Short-Term Assets $170.0K $70.00K $20.00K
YoY Change 250.0%
Inventory
Prepaid Expenses $165.0K $74.00K $18.00K
Receivables
Other Receivables
Total Short-Term Assets $1.452M $1.732M $2.373M
YoY Change 327.06% -27.01% 451.86%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $76.00K $105.0K
YoY Change -27.62%
Total Long-Term Assets $0.00 $0.00 $105.0K
YoY Change -100.0% -100.0% 5.0%
TOTAL ASSETS
Total Short-Term Assets $1.452M $1.732M $2.373M
Total Long-Term Assets $0.00 $0.00 $105.0K
Total Assets $1.452M $1.732M $2.478M
YoY Change 314.86% -30.1% 367.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $808.0K $585.0K $297.0K
YoY Change 7980.0% 96.97%
Accrued Expenses $816.0K $505.0K $132.0K
YoY Change 1260.0% 282.58% 164.0%
Deferred Revenue
YoY Change
Short-Term Debt $250.0K $250.0K
YoY Change -55.36%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.909M $1.375M $467.0K
YoY Change 198.28% 194.43% -29.24%
LONG-TERM LIABILITIES
Long-Term Debt $289.0K $287.0K $300.0K
YoY Change -4.33% 2900.0%
Other Long-Term Liabilities $40.00K $40.00K $30.00K
YoY Change 33.33%
Total Long-Term Liabilities $3.048M $3.038M $3.327M
YoY Change -8.69% 33170.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.909M $1.375M $467.0K
Total Long-Term Liabilities $3.048M $3.038M $3.327M
Total Liabilities $4.957M $4.413M $3.794M
YoY Change 674.53% 16.32% 466.27%
SHAREHOLDERS EQUITY
Retained Earnings -$14.49M -$13.67M -$8.569M
YoY Change 59.49%
Common Stock $30.00K $30.00K $6.000K
YoY Change 400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.505M -$2.681M -$1.316M
YoY Change
Total Liabilities & Shareholders Equity $1.452M $1.732M $2.478M
YoY Change 314.86% -30.1% 367.55%

Cashflow Statement

Concept 2016 Q1 2015 Q4 2014 Q4
OPERATING ACTIVITIES
Net Income -$824.0K -$730.0K -$980.0K
YoY Change -62.39% -25.51% 4800.0%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$540.0K -$860.0K -$1.170M
YoY Change -41.3% -26.5% -1270.0%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$500.0K
YoY Change -100.0% 257.14%
Cash From Investing Activities $0.00 -$500.0K
YoY Change -100.0% 233.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 410.0K
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -540.0K -860.0K -1.170M
Cash From Investing Activities 0.000 -500.0K
Cash From Financing Activities 0.000 0.000 410.0K
Net Change In Cash -540.0K -860.0K -1.260M
YoY Change 10.2% -31.75% 2420.0%
FREE CASH FLOW
Cash From Operating Activities -$540.0K -$860.0K -$1.170M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q2 dei Entity Public Float
EntityPublicFloat
75429
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29892806
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2014 snbp Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
25000
CY2015 snbp Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
375000
CY2015Q4 snbp Capital Stock Shares Authorized
CapitalStockSharesAuthorized
110000000
CY2015Q4 snbp Common Shares Issued Upon Conversion Of Notes Payable
CommonSharesIssuedUponConversionOfNotesPayable
2466667
CY2015 snbp Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.103
CY2014 snbp Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.016
CY2015 snbp Effective Income Tax Rate Reconciliation State Tax True Up Rate Percent
EffectiveIncomeTaxRateReconciliationStateTaxTrueUpRatePercent
0.053
CY2014 snbp Effective Income Tax Rate Reconciliation State Tax True Up Rate Percent
EffectiveIncomeTaxRateReconciliationStateTaxTrueUpRatePercent
0
CY2015 snbp Increase Decrease In Income And Other Taxes Receivable
IncreaseDecreaseInIncomeAndOtherTaxesReceivable
610000
CY2014 snbp Increase Decrease In Income And Other Taxes Receivable
IncreaseDecreaseInIncomeAndOtherTaxesReceivable
9000
CY2015 snbp Increase Decrease In Rebates Receivable
IncreaseDecreaseInRebatesReceivable
CY2014 snbp Increase Decrease In Rebates Receivable
IncreaseDecreaseInRebatesReceivable
-47000
CY2015Q4 snbp Interest Payable Noncurrent
InterestPayableNoncurrent
39000
CY2014Q4 snbp Interest Payable Noncurrent
InterestPayableNoncurrent
27000
CY2015Q3 snbp Merger Agreement Ownership Percentage By Former Shareholders
MergerAgreementOwnershipPercentageByFormerShareholders
0.988
CY2015Q3 snbp Merger Number Of Shares Called By Rights
MergerNumberOfSharesCalledByRights
28442484
CY2015Q3 snbp Merger Number Of Shares For Every Cancelled Share
MergerNumberOfSharesForEveryCancelledShare
4
CY2015 snbp Money Market Funds Price Per Share Sought To Maintain
MoneyMarketFundsPricePerShareSoughtToMaintain
1
CY2015 dei Trading Symbol
TradingSymbol
snbp
CY2015 dei Entity Registrant Name
EntityRegistrantName
Sun BioPharma, Inc.
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001029125
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
13000
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10943000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
7264000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105000
CY2015Q4 snbp Working Capital
WorkingCapital
357000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
585000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
297000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
505000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
132000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
933000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
70000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26000
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
42000
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
50000
CY2015 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28000
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8480267
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12704420
CY2015Q4 us-gaap Assets
Assets
1808000
CY2014Q4 us-gaap Assets
Assets
2478000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
1732000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
2373000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
925000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1654000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2694000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-729000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1040000
CY2015Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2550000
CY2015Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2550000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14202531
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29892806
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5688927
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29892806
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5688927
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4897000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3544000
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk</div></div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash and cash equivalents. Cash and cash equivalents are primarily deposited in demand and money market accounts. At times, such deposits may be in excess of insured limits. Investments in money market funds are not considered to be bank deposits and are not insured or guaranteed by the federal deposit insurance company or other government agencies. These money market funds seek to preserve the value of the investment at $1.00 per share; however, it is possible to lose money investing in these funds. The Company has not experienced any losses on its deposits of cash and cash equivalents.</div></div></div></div></div></div></div></div></div></div></div>
CY2015Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2775000
CY2014Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3000000
CY2015 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
226000
CY2014 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
101000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3811000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2620000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3395000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2395000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
32000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
236000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
152000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
148000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
38000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
35000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3811000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2620000
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-7000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-11000
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.29
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.385
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.001
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.061
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
500000
CY2014Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3100000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-108000
CY2015 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
CY2014 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2592000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1079000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5683000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3639000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-756000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
74000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
18000
CY2015Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
733000
CY2014Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
108000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
681000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-131000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
45000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5000
CY2015 us-gaap Interest Expense
InterestExpense
183000
CY2014 us-gaap Interest Expense
InterestExpense
184000
CY2015 us-gaap Interest Paid
InterestPaid
145000
CY2014 us-gaap Interest Paid
InterestPaid
106000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
35000
CY2014Q4 us-gaap Interest Payable Current
InterestPayableCurrent
38000
CY2015 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
8000
CY2014 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
6000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1808000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2478000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1375000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
467000
CY2015Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3114000
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3327000
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
300000
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
300000
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risks and Uncertainties</div></div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (&#x201c;FDA&#x201d;) in the United States, the Therapeutic Goods Administration (&#x201c;TGA&#x201d;) in Australia, the European Medicines Agency (&#x201c;EMA&#x201d;) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years, and is normally expected to involve substantial expenditures.</div></div> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have incurred losses of $13.7 million since SBR&#x2019;s inception in 2011. For the year ended December 31, 2015, we incurred a net loss and negative cash flows from operating activities of $4.9 million and $3.9 million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and seek to commercialize our primary product candidate, SBP-101</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">. As of December 31, 2015, we had cash and cash equivalents of $925,000, working capital of $357,000 and shareholders&#x2019; deficit of $2.7 million. We believe our cash and cash equivalents as of December 31, 2015, will be sufficient to fund our planned operations through the first quarter of 2016. The Company&#x2019;s principal sources of cash have included the issuance of convertible debt and equity securities. </div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-101 product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-101 product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note 3 entitled &#x201c;Liquidity and Management&#x2019;s Plans.&#x201d;</div></div></div>
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2675000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2815000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-501000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3897000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3343000
us-gaap Net Income Loss
NetIncomeLoss
-13700000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-4927000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-3531000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-239000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-194000
CY2015 us-gaap Notes Assumed1
NotesAssumed1
250000
CY2014 us-gaap Notes Assumed1
NotesAssumed1
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-5444000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-3445000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
76000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
105000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
30000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-13000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-64000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-16000
CY2015 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
CY2014 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9000
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12000
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
CY2015 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2014 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
501000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
762000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
424000
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
400000
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2852000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2366000
CY2013Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
700000
CY2014Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2400000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1513000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2015 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
CY2014 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2391000
CY2015 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
500000
CY2014 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13667000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8569000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
976000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
196000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5722264
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3463600
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.27
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4773616
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
780000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5340000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.18
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5043600
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6851352
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5487752
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3463600
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.27
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.23
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.20
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.22
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.24
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.32
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
3463600
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
3463600
CY2015Q4 us-gaap Share Price
SharePrice
0.32
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2224
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
0
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.06
CY2015Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
5342224
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.18
CY2015 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P8Y240D
CY2015Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
0.27
CY2015 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y240D
CY2015Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
250000
CY2014Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
CY2014Q4 us-gaap Short Term Investments
ShortTermInvestments
499000
CY2015Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
132964
CY2014Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
400000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2143600
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2590536
CY2015 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
-250000
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
101000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
226000
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
91000
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
42000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1513000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
493000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
693000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-2681000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-1316000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
1413000
CY2015Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
CY2014Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
94000
CY2015 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
CY2014 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-2000
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 9pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div></div><div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div>
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1200000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1300000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14073174
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5109644

Files In Submission

Name View Source Status
0001437749-16-027017-index-headers.html Edgar Link pending
0001437749-16-027017-index.html Edgar Link pending
0001437749-16-027017.txt Edgar Link pending
0001437749-16-027017-xbrl.zip Edgar Link pending
ex10-9.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
graph1.jpg Edgar Link pending
graph2.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snbp-20151231.xml Edgar Link completed
snbp-20151231.xsd Edgar Link pending
snbp-20151231_cal.xml Edgar Link unprocessable
snbp-20151231_def.xml Edgar Link unprocessable
snbp-20151231_lab.xml Edgar Link unprocessable
snbp-20151231_pre.xml Edgar Link unprocessable
snbp20151231_10k.htm Edgar Link pending